View More Recent Stories
-
Mizuho Reiterates Outperform Rating on ResMed (RMD)
-
Baird Reiterates Outperform Rating on ResMed (RMD)
-
ResMed (RMD) PT Raised to $224 at RBC Capital
-
Needham Reiterates Hold Rating on ResMed (RMD)
-
Oppenheimer Reiterates Perform Rating on ResMed (RMD)
-
Needham Reiterates Hold Rating on ResMed (RMD)
-
ResMed (RMD) PT Raised to $250 at Mizuho
-
Baird Reiterates Outperform Rating on ResMed (RMD)
-
Baird Starts ResMed (RMD) at Outperform
-
ResMed (RMD) option IV flat as share price down 4.8%
-
Needham Reiterates Hold Rating on ResMed (RMD)
-
Wolfe Research Downgrades ResMed (RMD) to Underperform
-
Needham Downgrades ResMed (RMD) to Hold
-
ResMed Management says GLP-1s are a tailwind now in meetings with William Blair
-
Increasing unusual put option volume: LUNR BEN URBN VIPS BJ TPR RMD BBAI ARRY WOLF SANA NTR
-
ResMed (RMD:AU) (RMD) PT Raised to AUD35 at CLSA
-
ResMed (RMD:AU) (RMD) PT Raised to AUD206 at RBC Capital
-
ResMed (RMD) Reports In-Line Q4 EPS
-
Oppenheimer Downgrades ResMed (RMD) to Perform
-
ResMed (RMD) July out of the money puts active as share price down 12%
-
Midday movers: Apple, Eli Lilly rise; Coinbase falls
-
ResMed, Inspire Medical slump after Lilly's positive Zepbound data; Citi downgrades
-
ResMed (RMD), Inspire Medical (INSP) sink following Lilly's sleep apnea results
-
Citi Downgrades ResMed (RMD:AU) (RMD) to Neutral
-
ResMed (RMD): PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
-
6 MedTech stocks to own - KeyBanc
